DANIS-3
12 Apr 2022
Trial Summary
daNIS-3: An open-label, multi-center, phase II platform study evaluating the efficacy and safety of NIS793 and other new investigational drug combinations with standard of care anti-cancer therapy for the second line treatment of metastatic colorectal cancer (mCRC)
Acronym:
daNIS-3
ACTRN/NCT /ethics:
NCT04952753
Scientific title:
Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC (daNIS-3)
Sponsor / Cooperative group:
Novartis Pharmaceuticals
Trial & Patient Characteristics
| Cancer Type | Bowel and colon |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | - |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Metastatic or Widespread |
| Anticipated Start Date | 2021-11-15 |
| Anticipated End Date | 2025-02-17 |
Participating Hospitals
| Hospital | Cancer Research SA |
|---|---|
| Clinical Trial Coordinator | Kelly Mead |
| admin@cancerresearchsa.com.au | |
| Phone | 08 8359 2565 |
| Principal Investigator | A/Prof Rohit Joshi |
| Recruitment Status | Recruiting |